BP003134: Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and GLYDGMEHL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003131: Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&MAGE-A10 (GLYDGMEHL) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and GLYDGMEHL peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP005411: Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and GVYDGREHTV peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Monomer protein with the C-His-Avi tag at 1 ug/ml (100 ul/Well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Antibody protein with the C-hFc tag with the EC50 of 4.4 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004310: Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and GVYDGREHTV peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Tetramer protein with the C-His-Avi tag at 1 ug/ml (100 ul/Well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&MAGE-A4 (GVYDGREHTV) Antibody protein with the C-hFc tag with the EC50 of 3.8 ng/ml determined by ELISA (QC Test). The affinity constant of 8.49 pM as determined in SPR assay (Biacore T200).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004541: Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and CLGGLLTMV peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer protein with the C-His-Avi tag at 2 ug/ml (100 ul/well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody protein with the C-hFc tag with the EC50 of 18.4 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP005060: Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and CLGGLLTMV peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer protein with the C-His-Avi tag at 1 ug/ml (100 ul/Well) on the plate. Dose response curve for the recombinant Anti-HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody protein with the C-hFc tag with the EC50 of 5.0 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004137: Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004139: Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and YMLDLQPET peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004129: Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FLLTRILTI peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP004068: Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)and FLLTRILTI peptide) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.